Axsome Therapeutics, Inc. (AXSM): Capital Expenditures
$480.0K
Year ended 2025-12-31
$700.0K
Trailing 12 months to 2026-06-30
-11.9%
3-year compound annual growth
+59.9%
5-year compound annual growth
+37.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $480.0K | +77.8% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $270.0K | -53.6% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $582.0K | -17.1% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $702.0K | +127.9% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $308.0K | +571.2% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $45.9K | +184.7% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $16.1K | -50.7% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $32.7K | +230.3% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $9.9K | -90.5% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $104.6K | +417.8% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $20.2K | n/a | 2018-03-07, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $480.0K | +77.8% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $214.0K | +375.6% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
| Insmed Inc (INSM) | 2025-12-31 | $32.56M | +48.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $6.00M | -14.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.57M | +466.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.34M | +84.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $34.88M | -15.0% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $14.15M | +41.1% |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗